Inovio Pharmaceuticals (NYSE:INO) was upgraded by Zacks from a “neutral” rating to an “outperform” rating in a report released on Thursday, American Banking & Market News reports. The firm currently has a $4.00 price target on the stock. Zacks‘s price target would indicate a potential upside of 8.40% from the stock’s previous close. Inovio Pharmaceuticals Inc. (NYSEMKT:INO) shares after opening at $3.50 moved to $3.55 on last trade day and at the end of the day closed at $3.23. Company price to sales ratio in past twelve months was calculated as 49.97 and price to cash ratio as 12.83. Inovio Pharmaceuticals Inc. (NYSEMKT:INO) showed a negative weekly performance of -5.83%.
CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical research and development company specializing in oncology, announced it has initiated a pivotal global Phase 3 clinical trial to evaluate the efficacy and safety of aldoxorubicin as a second-line treatment for patients with soft tissue sarcoma (STS) under a Special Protocol Assessment with the FDA. CytRx Corporation (NASDAQ:CYTR) shares fell -7.52% in last trading session and ended the day on $3.69. CYTR return on equity ratio is recorded as -287.90% and its return on assets is -146.40%. CytRx Corporation (NASDAQ:CYTR) yearly performance is 27.24%.
Sangamo Biosciences (NASDAQ:SGMO) Insider Philip D. Gregory sold 15,000 shares of the company’s stock in a transaction dated Friday, March 21st. The stock was sold at an average price of $22.38, for a total transaction of $335,700.00. Following the transaction, the insider now directly owns 109,347 shares of the company’s stock, valued at approximately $2,447,186. Sangamo Biosciences, Inc. (NASDAQ:SGMO) shares moved down -5.05% in last trading session and was closed at $18.80, while trading in range of $18.01 – $20.12. Sangamo Biosciences, Inc. (NASDAQ:SGMO) year to date (YTD) performance is 35.35%.
TherapeuticsMD, Inc. (NYSEMKT:TXMD), a women’s health care product company, announced the pricing of a previously announced underwritten secondary public offering of 9,000,000 shares of its common stock, offered at a price of $7.10 per share. TherapeuticsMD Inc. (NYSEMKT:TXMD) weekly performance is -22.08%. On last trading day company shares ended up $6.21. TherapeuticsMD Inc. (NYSEMKT:TXMD) distance from 50-day simple moving average (SMA50) is -5.13%. Analysts mean target price for the company is $8.75.